{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T23:38:25Z","timestamp":1775345905232,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,2,6]],"date-time":"2002-02-06T00:00:00Z","timestamp":1012953600000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"AstraZeneca, Sweden"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>An association between Irritable Bowel Syndrome (IBS) and bronchial hyper\u2010responsiveness has been suggested. Only a few studies have specifically studied the association between IBS and asthma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To estimate the incidence rate of IBS among asthma patients and to compare it with the general population. We also examined the association between use of asthma drugs, specifically corticosteroids, and IBS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Population\u2010based cohort study using the General Practice Research Database (GPRD) in the UK. The cohort comprised a random sample of 50\u2009000 asthma patients aged 10\u201379 years and a similar number of sex\u2010and age\u2010matched individuals free of asthma and identified from the source population. A nested case\u2013control analysis was performed within the asthma cohort to examine the association between asthma drugs and IBS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The incidence rate of IBS in the asthma cohort was 2.5 per 1000 persons\u2010years and 2.0 in the general population. The relative risk (RR) was 1.3 (95% CI 1.1\u20131.5). A medical history of neurotic and psychologic disorders, pain\u2010related diseases and gastroenteritis were all associated with the occurrence of IBS. In the asthma cohort, current users of oral steroids presented a RR of 0.5 (95% CI 0.2\u20131.2) for developing IBS. The risk estimate was similar in short\u2010and long\u2010term users of steroids.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We found a slightly increased risk of IBS in asthma patients compared to the general population and that the risk of IBS was reduced by use of oral steroids in asthma patients. Additional studies in the general population are necessary in order to confirm whether use of corticosteroids irrespective of asthma has a protective effect on the risk of IBS. Copyright \u00a9 2001 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.666","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T23:13:41Z","timestamp":1030317221000},"page":"31-35","source":"Crossref","is-referenced-by-count":40,"title":["Risk of irritable bowel syndrome among asthma patients"],"prefix":"10.1002","volume":"11","author":[{"given":"Consuelo","family":"Huerta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Alberto Garc\u00eda","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary\u2010Ann","family":"Wallander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saga","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,2,6]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"Current Estimates from the National Health Interview Survey 12\/94. Vital Health Statistics US Dept of Health and Human Services Public Health Services 1993;83."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb00178.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90373-9"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90584-8"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.6.770"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/bega.1999.0037"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00701.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.302.6779.766"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.54.5.413"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7183.565"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.666","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:56:16Z","timestamp":1700394976000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1002\/pds.666"],"URL":"https:\/\/doi.org\/10.1002\/pds.666","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}